Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Primary listing
Employees
2,498
Headquarters
Website
Guardant Health Metrics
BasicAdvanced
$17bn
-
-$3.40
1.49
-
Price and volume
Market cap
$17bn
Beta
1.49
52-week high
$135.00
52-week low
$40.36
Average daily volume
2.4m
Financial strength
Current ratio
4.681
Quick ratio
4.245
Long term debt to equity
-925.884
Total debt to equity
-941.364
Interest coverage (TTM)
-83.85%
Profitability
EBITDA (TTM)
-408.155
Gross margin (TTM)
64.90%
Net profit margin (TTM)
-40.10%
Operating margin (TTM)
-41.39%
Effective tax rate (TTM)
0.27%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-17.15%
Return on equity (TTM)
200.62%
Valuation
Price to revenue (TTM)
15.521
Price to book
-95.71
Price to tangible book (TTM)
-61.05
Price to free cash flow (TTM)
-70.705
Free cash flow yield (TTM)
-1.41%
Free cash flow per share (TTM)
-1.864
Growth
Revenue change (TTM)
39.56%
Earnings per share change (TTM)
0.78%
3-year revenue growth (CAGR)
30.85%
3-year earnings per share growth (CAGR)
-19.36%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
Gamehost Receives Final Court Order Authorizing Sale to Pure Casino Entertainment
Newsfile Corp·4 days ago
Gamehost Shareholders Approve Sale to Pure Casino Entertainment
Newsfile Corp·1 week ago
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs